Yes, doneWould it make sense to sticky this megathread in the resources section so it doesn’t get lost & stale, @Hutan?
Yes, doneWould it make sense to sticky this megathread in the resources section so it doesn’t get lost & stale, @Hutan?
When is the deadline?
I agree with this.In an interim situation physicians can set up publishable studies, as I did. Using something like daratumumab is not simple. You have to know about plasma cells, otherwise you get the situation we got with rituximab with a mass of uninformed French physicians making the patients hypogammaglobulinaemic so that they got infections. Use of dara should probably be restricted to physicians with good understanding of immunology at least until a formal license is out and I would tend to argue, even after.
I was assuming that there will be at least some private immunologists/rheumatologists who begin providing dara if it is successful in phase 2.I agree with this.
Patients must not let our desperation cloud our judgement and caution. Most long-termers have made that mistake, including me.
Unfortunately it is still being made by some patient support groups and 'patient-led' research.
I was thinking about being more specific about what therapeutic enthusiasms patients and carers need protecting from (diaries etc.).